ABX464 shows excellent long-term efficacy data in Abivax's phase 2B maintenance trial in ulcerative colitis
-
Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacy
-
Favorable safety and tolerability profile continues to support ABX464 chronic use potential
-
Launch of global phase 3 program with ABX464 in ulcerative colitis in preparation, with end-of-Phase-2 US FDA meeting in Q4 2021 and EMA Scientific Advice in early Q1 2022
-
Abivax’s late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021 now publicly available